RBC Capital raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $82 from $77 and keeps an Outperform rating on the shares. There is growing enthusiasm around the company’s obesity asset ‘913, with phase 2 data from Novo Nordisk’s (NVO) INV-202 expected in the second half of this year and ‘913 entering phase 1 in Q1 of 2025, the analyst tells investors in a research note. RBC adds that tits deep dive analysis shows considerable structural and preclinical similarities between ‘913 and ‘202, with potential for ‘913 to be safer but likely not meaningfully less efficacious.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals’ Promising Cancer Drug Trial Results
- Corbus Pharmaceuticals price target raised to $80 from $60 at Oppenheimer
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
- Corbus Pharmaceuticals updated Phase 1 data for SYS-6002 to be presented at ASCO
- Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting